Adverse Events in the Tracheal Intubation in the Intensive Care Unit (INTUPROS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03916224 |
Recruitment Status :
Not yet recruiting
First Posted : April 16, 2019
Last Update Posted : April 16, 2019
|
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | April 4, 2019 | ||||||||||||||||
First Posted Date | April 16, 2019 | ||||||||||||||||
Last Update Posted Date | April 16, 2019 | ||||||||||||||||
Estimated Study Start Date | April 15, 2019 | ||||||||||||||||
Estimated Primary Completion Date | June 30, 2020 (Final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures |
Occurrence of major complications in the intubation process of patients admitted to Intensive Care Units. [ Time Frame: 28 days ] This study will analyze the prevalence of major complications related to intubation technique in the participant critical care units. This information will be useful in order to determinate the risk factors associated.
|
||||||||||||||||
Original Primary Outcome Measures | Same as current | ||||||||||||||||
Change History | No Changes Posted | ||||||||||||||||
Current Secondary Outcome Measures |
|
||||||||||||||||
Original Secondary Outcome Measures | Same as current | ||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title | Adverse Events in the Tracheal Intubation in the Intensive Care Unit | ||||||||||||||||
Official Title | Clinical Practice and Risk Factors for Major Adverse Events in the Tracheal Intubation in the Intensive Care Unit: A Prospective Multicentre Study | ||||||||||||||||
Brief Summary | The airway management is essential in the Critical Care setting, both normal and difficult airway patients. Intubation is a risk procedure in which a great number of complications may occur, including death. The poor physiological reserve of critical patients may suppose an additional handicap to carry out successfully intubation. The purpose of this study is to analyze the prevalence and risk factors for major complications in the intubation process in the Intensive Care Unit (ICU). In addition, the investigators will assess the impact of preoxygenation and the use of videolaryngoscope on the occurrence of major and minor complications. Finally, this study will review the drug protocols used in each participant ICU during intubation process. |
||||||||||||||||
Detailed Description | The correct airway and difficult airway management are essential in the Critical Care setting. Intubation is a procedure frequently carried out by intensivist and a great number of complications have been related. Serious complications can occur, including the development of severe hypoxemia, arrhythmias, cardiac arrest with permanent anoxic brain damage or death. Additionally the poor physiological reserve of critically ill patients and the variable operator experience, means that this technique must be considered a risk event in critical patients. In recent years, it has been taken more and more importance of preoxygenation as a strategy that can avoid major complications in the intubation process. Similarly, the use of devices that facilitate intubation such as videolaryngoscopy, has been included in difficult airway management protocols. If the use of videolaryngoscopy compared with traditional laryngoscopy is associated with a higher success rate and a lower incidence of complications, still remains controversial. The investigators want to know the prevalence and risk factors for major complications in the intubation process of patients admitted to Intensive Care Unit (ICU). In addition, this study will try to assess the use and impact of both preoxygenation and videolaryngoscope in the intubation process. |
||||||||||||||||
Study Type | Observational [Patient Registry] | ||||||||||||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||||||||||||||
Target Follow-Up Duration | 28 Days | ||||||||||||||||
Biospecimen | Not Provided | ||||||||||||||||
Sampling Method | Non-Probability Sample | ||||||||||||||||
Study Population | Critically ill patients, older than 18 years old, that are intubated at the participating Units. | ||||||||||||||||
Condition |
|
||||||||||||||||
Intervention | Not Provided | ||||||||||||||||
Study Groups/Cohorts | Intubated critically ill patients
Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
|
||||||||||||||||
Publications * | Not Provided | ||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status | Not yet recruiting | ||||||||||||||||
Estimated Enrollment |
1000 | ||||||||||||||||
Original Estimated Enrollment | Same as current | ||||||||||||||||
Estimated Study Completion Date | September 30, 2020 | ||||||||||||||||
Estimated Primary Completion Date | June 30, 2020 (Final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||
Sex/Gender |
|
||||||||||||||||
Ages | 18 Years and older (Adult, Older Adult) | ||||||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||||||
Contacts |
|
||||||||||||||||
Listed Location Countries | Not Provided | ||||||||||||||||
Removed Location Countries | |||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number | NCT03916224 | ||||||||||||||||
Other Study ID Numbers | 1149-N-18 | ||||||||||||||||
Has Data Monitoring Committee | Not Provided | ||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||
IPD Sharing Statement |
|
||||||||||||||||
Responsible Party | José Garnacho Montero, Spanish Network for Research in Infectious Diseases | ||||||||||||||||
Study Sponsor | Spanish Network for Research in Infectious Diseases | ||||||||||||||||
Collaborators | Not Provided | ||||||||||||||||
Investigators |
|
||||||||||||||||
PRS Account | Spanish Network for Research in Infectious Diseases | ||||||||||||||||
Verification Date | April 2019 |